TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07851688: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection Following Single and Multiple Dosing in Healthy Trial Participants and Multiple Dosi

Sponsor: Gan & Lee Pharmaceuticals. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 106 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07851688 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07851688 Rescue Dossier →